Information Provided By:
Fly News Breaks for August 6, 2019
PODD
Aug 6, 2019 | 06:28 EDT
JPMorgan analyst Robbie Marcus upgraded Insulet to Overweight from Neutral and raised his price target for the shares to $155 from $120. Following the company's "very strong" Q2 results, the analyst expects Dash to support 20%-plus U.S. OmniPod growth through 2020, with Horizon sustaining 20%-plus growth in 2021. Dash and pharmacy access are fundamentally changing Insulet's adoption curve, Marcus tells investors in a research note. He believes the bull case on the stock is playing out.
News For PODD From the Last 2 Days
There are no results for your query PODD
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.